SynthesisFrontiers in epidemiology2026
Neutrophil-to-lymphocyte ratio for the clinical management of dengue: a systematic review and meta-analysis.
Synthesis in Frontiers in epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dengue fever (DF) remains a major global public health concern, especially in tropical and low-resource settings. The neutrophil-to-lymphocyte ratio (NLR) has been proposed as an accessible biomarker for diagnosis and severity assessment, but the existing evidence is heterogeneous. To summarize the current evidence on the behavior of the NLR in DF. Methods: This study conducted a systematic search in five databases for observational studies published until April 2024. Inclusion and exclusion criteria were based on predefined eligibility criteria, and quality and methodological assessment were expressed using the Newcastle-Ottawa Scale. Data was pooled using a random-effects model and results generalized as applicable, when pooling could not be carried out. A summary receiver operating characteristic curve (sROC) was obtained to assess the diagnostic accuracy of NLR for distinguishing DF from COVID-19. The certainty of evidence was graded using the GRADE system. Result: A total of 6,166 participants from 15 observational studies were included, all with low risk of bias. A single study showed a higher NLR in dengue vs. healthy controls (Bhattarai, 2023; MD: 1.29; 95% CI: 0.87 to 1.71), with moderate certainty. The SROC curve for dengue vs. COVID-19 (2 studies, Conclusion: For prognosis, severe dengue showed a small, but significant NLR decrease compared with dengue with warning signs (MD: -0.54; 95% CI: -0.91 to -0.17, I2 = 0%), with very low certainty. NLR may serve as a supportive diagnostic biomarker for dengue. However, its prognostic value remains uncertain, highlighting the need for large, prospective studies to validate cutoff points and clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.